Several studies have reported that IDH mutations are associated with younger age at diagnosis and limited genome alterations among patients with WHO grade II/III gliomas and GBMs, which may bias the disease outcome (Figure 3C,D) [1,2,94,95]. The gene discussed is IDH2; the disease is central nervous system cancer.